Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

News Conference News TCT 2019

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

Michael O'Riordan

September 30, 2019

https://www.tctmd.com/news/ideal-lm-probes-short-dapt-and-bioabsorbable-polymer-stent-left-main-disease

News Conference News TCT 2019

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Michael O'Riordan

September 26, 2019

News Conference News TCT 2016

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

Yael L. Maxwell

November 08, 2016

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

News Conference News TCT 2015

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

Yael L. Maxwell

October 12, 2015

Presentation TCT 2014

I-LOVE-IT 2: A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease

Presenter: Mitchell W. Krucoff, Giulio G. Stefanini, Bo Xu

September 16, 2014

Presentation TCT 2014

2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromi___

Presenter: Clemens von Birgelen

September 16, 2014

Presentation TCT 2014

Cobalt-Chromium Sirolimus-Eluting Platforms VII: MiStent

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil, John A. Ormiston

September 15, 2014

Presentation TCT 2014

Cobalt-Chromium Sirolimus-Eluting Platforms VI: Ultimaster

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil, Shigeru Saito

September 15, 2014

Presentation TCT 2014

Cobalt-Chromium Sirolimus-Eluting Platforms V: Alex Eluting Stent

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil

September 15, 2014

Presentation TCT 2014

Cobalt-Chromium Sirolimus-Eluting Platforms IV: Firehawk

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil, Bo Xu

September 15, 2014

Presentation TCT 2014

Cobalt-Chromium Sirolimus-Eluting Platforms III: Inspiron

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil, Pedro A. Lemos

September 15, 2014

Presentation TCT 2014

Cobalt-Chromium Sirolimus-Eluting Platforms II: ORSIRO

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil, Stephan Windecker

September 15, 2014

Presentation TCT 2014

Cobalt-Chromium Sirolimus-Eluting Platforms I: BioMime

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil, Ricardo A. Costa

September 15, 2014

News Conference News TCT 2014

COMPARE II: BES, EES Show Similar Outcomes at Three Years

September 13, 2014

News Conference News TCT 2013

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

November 03, 2013

Presentation TCT 2013

Real-World Comparison of Clinical Outcomes of Patients who Received New Generation Platinum Chromium Everolimus-Eluting Stent versus Cobalt Chromium Everolimus-Eluting Stent

Presenter: Ruogu Li, Adrian Low, Chi Hang Lee, Mark Chan, Swee Guan Teo, Koo Hui Chan, Mark Richards Arthur, Huay Cheem Tan

January 31, 2013

Advertisement

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Ultrathin-Strut Orsiro Stent as Good as BioMatrix: BIODEGRADE

IDEAL-LM Probes Short DAPT and a Bioabsorbable-Polymer Stent in Left Main Disease

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

ABSORB III: Novel Bioresorbable Scaffold as Good as Standard-of-Care DES

I-LOVE-IT 2: A Prospective, Randomized Trial of a Biodegradable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent Versus a Durable Polymer, Cobalt Chromium, Sirolimus-Eluting Stent in Patients with Coronary Artery Disease

2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromi___

Cobalt-Chromium Sirolimus-Eluting Platforms VII: MiStent

Cobalt-Chromium Sirolimus-Eluting Platforms VI: Ultimaster

Cobalt-Chromium Sirolimus-Eluting Platforms V: Alex Eluting Stent

Cobalt-Chromium Sirolimus-Eluting Platforms IV: Firehawk

Cobalt-Chromium Sirolimus-Eluting Platforms III: Inspiron

Cobalt-Chromium Sirolimus-Eluting Platforms II: ORSIRO

Cobalt-Chromium Sirolimus-Eluting Platforms I: BioMime

COMPARE II: BES, EES Show Similar Outcomes at Three Years

Meta-analysis: Most DES Safer Than BMS, Biodegradability Offers No Extra Benefit

Real-World Comparison of Clinical Outcomes of Patients who Received New Generation Platinum Chromium Everolimus-Eluting Stent versus Cobalt Chromium Everolimus-Eluting Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content